Compare Accenture plc (ACN) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Dolby Laboratories, Inc. — how do they compare? Accenture plc trades at $138.41 (market cap $86.98B), while Dolby Laboratories, Inc. trades at $50.69 (market cap $4.66B). The key difference: Accenture plc is far larger — about 18.7× Dolby Laboratories, Inc.'s market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | DLB | |
|---|---|---|
Market Cap | $86.98B | $4.66B |
Sector | Technology | Industrials |
52-Week High | $303.33 | $76.79 |
52-Week Low | $124.41 | $49.31 |
Enterprise Value | $85.20B | $4.12B |
Dividend Yield | 4.59% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.
Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
